about
sameAs
Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor Maraviroc ComplexClinical significance of HIV-1 coreceptor usage.Bioinformatic analysis of HIV-1 entry and pathogenesis.Access denied? The status of co-receptor inhibition to counter HIV entryInfection of female primary lower genital tract epithelial cells after natural pseudotyping of HIV-1: possible implications for sexual transmission of HIV-1.Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applicationsVaccinia and other viruses with available vaccines show marked homology with the HIV-1 envelope glycoprotein: the prospect of using existing vaccines to stem the AIDS pandemic.X4 viruses are frequently archived in patients with long-term HIV infection but do not seem to influence the "inflamm-aging" process.Lead Screening for HIV of C-C Chemokine Receptor Type 5 Receptor Inhibited by Traditional Chinese Medicine.Lead screening for CXCR4 of the human HIV infection receptor inhibited by traditional Chinese medicineTropism testing in the clinical management of HIV-1 infection.A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individualsEvaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.Design, synthesis and biological evaluation of novel piperazine derivatives as CCR5 antagonists.Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.Analysis of HIV tropism in Ugandan infants.The isolation of novel phage display-derived human recombinant antibodies against CCR5, the major co-receptor of HIVPersistence and emergence of X4 virus in HIV infection.Fifteen years later: hard and soft selection sweeps confirm a large population number for HIV in vivo.Insight derived from molecular dynamics simulations into molecular motions, thermodynamics and kinetics of HIV-1 gp120Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: implications for future treatment optionsReduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa.In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068.Expression of CCR5, CXCR4 and DC-SIGN in Cervix of HIV-1 Heterosexually Infected Mexican Women.Oral CCR5 inhibitors: will they make it through?Predicted HIV-1 coreceptor usage among Kenya patients shows a high tendency for subtype d to be cxcr4 tropic.Improving Clinical Laboratory Efficiency: Introduction of Systems for the Diagnosis and Monitoring of HIV Infection.Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249.New approaches in the treatment of HIV/AIDS - focus on maraviroc and other CCR5 antagonistsRelationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection.The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort studyHIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.Inhibition of HIV type 1 replication by human T lymphotropic virus types 1 and 2 Tax proteins in vitro.Novel AIDS therapies based on gene editing.Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in Spain.Determination of the high prevalence of Dual/Mixed- or X4-tropism among HIV type 1 CRF01_AE in Hong Kong by genotyping and phenotyping methods.
P2860
Q27679932-F90EB55C-457F-4090-B243-476CCA981F5CQ27691426-3931FDB6-93B8-47E2-AC1D-037C2E2B37AFQ27693321-75766C5B-11AB-4264-965A-7EA5888A3DBAQ28300187-4315F401-0C21-455F-B1EF-27720AFFE9EAQ30364549-3AF8ED45-31B6-4A52-A4FD-19A582EFCAE4Q30366071-FCAEE0DF-36FE-41B9-94E3-CC099D74C09BQ30406122-5048E2C7-2961-495F-B625-C6EE8442D128Q31117473-B8A1183A-3CB6-406A-8D61-6044A788C336Q33615005-ECCC2082-FCB7-4F4F-9F0E-E6D80AD93E59Q33791008-F54EC5E3-3362-44E4-AE8B-E1E089D700B1Q33869686-3DD3B23B-BBDD-4652-843C-EE65696B5F72Q34009093-9FC5997F-4F03-4FD7-A603-5A7A7AEB1287Q34045403-E02AE90D-319D-41D2-8209-AB95E17DE766Q34473072-23FF8EC6-3DDE-45FA-97A5-E3113318667BQ34545281-015C742E-45EA-461F-90DB-BD688BBC9A66Q34604941-ECC26F7C-9515-4A23-9ABC-DE1866FAFB0DQ34786687-84EAC621-5673-40D3-BC2B-8ED00FCF2DC4Q34939533-C3BF35EF-CFB1-41F0-9D04-93F8FC2C4F3EQ35055322-59000165-7A87-4B42-A4D8-5FB98B775D97Q35105761-FD807C3A-B3EA-483F-AD0C-77DFA0AA09EAQ35221774-04965E41-EF9C-476A-BCB8-69D5EB8C3F04Q35386184-4EB05A89-F0CB-45A1-AEC3-E399CA01B070Q35784750-2EF79A83-152D-429D-89D3-400A8F3AC72AQ35818419-D411416F-8192-4CD0-9276-C4BCE348AC08Q36086493-F5773738-E6E6-43F2-9175-4137C8D8476BQ36345852-E0AB6522-2D56-4D5A-A101-3B00372AC6F8Q36458354-A9511E1D-6674-4E50-8498-CCB9EFF1A741Q36480496-21E6F8B4-8884-4862-A961-550F46D4D066Q36481637-441ECECD-2F7E-4C52-87D5-707B0253F149Q36802500-C174B391-D444-42FD-9510-1EDC883F4AEEQ36823525-362CE46D-FA53-435E-BC7F-A01B89331BCFQ37163016-EF736363-9980-41DC-B31A-22EA4D63E31BQ37247686-EA304291-F760-4580-A547-19BE43FF8416Q37365672-E793B56B-56EE-4538-BD32-A8360D934907Q37525642-56EE2F05-2CE4-4672-8A8E-C94253D29BF5Q38894616-8F7DDD4B-9987-4E18-91C2-7909BEF31169Q39140209-0C612CBD-7BDB-4E24-AF8B-C3DCB19F672DQ39178072-A85B3684-3DCE-4093-9953-02617C298835Q39267946-C9DB87B1-4215-4AF9-95A9-BEFA9998CDCAQ39424156-C3EAEA6F-1607-40A2-BCF6-466E8ED860C9
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Assessing chemokine co-receptor usage in HIV
@ast
Assessing chemokine co-receptor usage in HIV
@en
Assessing chemokine co-receptor usage in HIV
@en-gb
Assessing chemokine co-receptor usage in HIV
@nl
type
label
Assessing chemokine co-receptor usage in HIV
@ast
Assessing chemokine co-receptor usage in HIV
@en
Assessing chemokine co-receptor usage in HIV
@en-gb
Assessing chemokine co-receptor usage in HIV
@nl
prefLabel
Assessing chemokine co-receptor usage in HIV
@ast
Assessing chemokine co-receptor usage in HIV
@en
Assessing chemokine co-receptor usage in HIV
@en-gb
Assessing chemokine co-receptor usage in HIV
@nl
P1476
Assessing chemokine co-receptor usage in HIV
@en
P2093
Eoin Coakley
Jeannette M Whitcomb
P356
10.1097/00001432-200502000-00003
P407
P577
2005-02-01T00:00:00Z